Stoke TherapeuticsAktie

ISIN: US86150R1077 | WKN: A2PLTL | Symbol: STOK
37,48
 
USD
02:00:00 Nasdaq
+7,55 %
+2,63 USD
Geldkurs 18.09.20
37,40 USD
400 Stk.
Briefkurs 18.09.20
37,46 USD
400 Stk.
Mehr Daten anzeigen
Smartbroker
NewsFlashAnzeige
Paukenschlag im URAN-SEKTOR! USA begrenzen IMPORTE! Diese URAN-AKTIE steht vor Explosion!

Stoke Therapeutics Chart

Neuigkeiten zur Stoke Therapeutics Inc Aktie

ZeitTitel
SmartbrokerJetzt auf smartbroker.de - ab 0 € pro Order handeln! Anzeige
09.09.20
Stoke Therapeutics to Present at Cantor Virtual Global Healthcare Conference
26.08.20
Stoke Therapeutics Announces Publication of Preclinical Data on STK-001 in the Journal Science Translational Medicine that Demonstrate Significant Improvements in Survival and Reductions in Seizure Frequency in a Dravet Syndrome Mouse Model
17.08.20
Stoke Therapeutics Announces Appointment of Garry E. Menzel, Ph.D., to its Board of Directors
10.08.20
Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
04.08.20
Stoke Therapeutics to Present at Upcoming Investor Conferences in August
09.07.20
Stoke Therapeutics Announces Publication of Data in the Journal Nature Communications That Support the Company’s Proprietary Approach to Addressing Severe Genetic Diseases by Precisely Upregulating Protein Expression
04.06.20
Stoke Therapeutics Appoints Julie Anne Smith to its Board of Directors
15.05.20
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
12.05.20
Stoke Therapeutics Presents Preclinical Data That Demonstrate In-Vitro and In-Vivo Target Engagement and Protein Upregulation in OPA1 Protein Deficiency, the Primary Cause of the Most Common Inherited Optic Nerve Disorder
23.03.20
Stoke Therapeutics Reports Full Year 2019 Financial Results and Provides Business Updates
24.02.20
Stoke Therapeutics to Present at 40th Annual Cowen Health Care Conference
07.01.20
Stoke Therapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference
23.12.19
Stoke Therapeutics Added to NASDAQ Biotechnology Index
07.12.19
Stoke Therapeutics Presents Preclinical Data From Studies of STK-001 That Showed Improvements in Survival and Reductions in Seizure Frequency in a Mouse Model of Dravet Syndrome
Insidertrade: :
Hier Upload von Dokumenten / Links zum Wertpapier: Upload

Nachrichten aus der Branche Biotechnologie

ZeitTitel
17:04 Uhr
Paul-Ehrlich-Institut: Impfstoff-Zulassung Ende 2020 oder Anfang 2021
17:00 Uhr
Immunomedics Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvy in Metastatic Urothelial Cancer
16:30 Uhr
Trodelvy Significantly Extends Survival in Phase 3 ASCENT Study of Metastatic Triple-Negative Breast Cancer
13:30 Uhr
Phase 3 NORA data of ZEJULA (niraparib) demonstrate significant PFS benefit, regardless of biomarker status, with an improved safety profile when given with individualized starting dose regimen in Chinese women with platinum-sensitive recurrent ovarian ca
08:19 Uhr
4 Impfstoff-News von der BioNTech-Aktie, der AstraZeneca-Aktie und der Valneva-Aktie
mehr Branchennachrichten »

Aktienkurs Stoke Therapeutics A2PLTL |

BörsenplatzNasdaq
Letzter Kurs37,48USD
Performance+7,55 %
Kurszeit02:00:00
Eröffnung36,10USD
Tageshoch37,88USD
Tagestief34,00USD
Vortageskurs34,85USD
Volumen617,66 Tsd.Stk.
52-Wochen Hoch35,00USD
52-Wochen Tief15,820USD
Anzahl Trades1.082
Performance 1 Monat+18,74 %
Performance 1 Jahr+40,58 %

Stammdaten zu Stoke Therapeutics

NameStoke Therapeutics Inc
KurznameStoke Therap
NamenszusatzRegistered Shs
KategorieAktien
AktientypStammaktien
WKNA2PLTL
SymbolSTOK
BrancheBiotechnologie
LandUSA USA
ReferenzwährungUSD
Aktienanzahl33,24 Mio.
Marktkapitalisierung1,25 Mrd.USD

Performance Stoke Therapeutics Aktie

ZeitKursPerf.
1 Tag37,48USD
+7,55 %
1 Woche31,93USD
+6,76 %
1 Monat28,71USD
+18,74 %
3 Monate23,030USD
+48,02 %
6 Monate20,250USD
+68,35 %
Lfd. Jahr28,32USD
+20,37 %
1 Jahr24,250USD
+40,58 %
mehr Performancedaten »
Adresse und Kontaktdaten
NameStoke Therapeutics Inc
StadtBedford, MA
LandUSA USA
Webseitewww.stoketherapeutics.com
Aktionäre interessieren sich auch für:
#WertpapierPerf. %
1.
Carl Zeiss Meditec
+1,00
2.
Humana
+1,29
3.
Vertex Pharmaceuticals
-2,24
4.
NanoRepro
-1,67
5.
Assembly Biosciences
-3,11
6.
Cleveland Biolabs
0,00
 
7.
Co-Diagnostics
+3,56
8.
Translate Bio
+0,20
9.
Atreca Registered (A)
+2,19
10.
CloudMD Software & Services
-4,31

Emissionsinformationen

Ausgabepreis14,00USD - 16,00USD
Emissionspreis18,000USD
Emissionsvolumen6.700.000Stück
ZeichnungsgebührNein
IPO Anmeldetag23.05.2019
IPO19.06.2019
PlatzierungÖffentlich